Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 1, 2005, Pages 7-17

  Persson, Frida ^a   Carlsson, Leif ^a   Duker, Göran ^a   Jacobson, Ingemar ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Kv 1.5; Kv4.3; Potassium channels; Whole cell voltage clamp

Indexed keywords

ANTIARRHYTHMIC AGENT; AZD 7009; ION CHANNEL; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; ELECTROPHYSIOLOGY; GENE; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HKCHIP2.2 GENE; HKV1.5 GENE; HKV4.3 GENE; HNAV1.5 GENE; IC 50; MEMBRANE CURRENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 21444458758     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000161405.37198.c1     Document Type: Article

References (27)

1. Witchel HJ, Hancox JC. Familial and acquired long QT syndrome and the cardiac delayed rectifier potassium current. Clin Exp Pharmacol Physiol. 2000;27:753-766.
2. Volders PGA, Vos MA, Szabo B, et al. Progress in the understanding of early afterdepolarisations and torsades de pointes: time to revise current concepts. Cardiovasc Res. 2000;46:376-392.
3. Gross GJ, Castle NA. Propafenone inhibition of human atrial myocyte repolarizing currents. J Mol Cell Cardiol. 1998;30:783-793.
4. Franqueza L, Valenzuela C, Delpon E, et al. Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. Br J Pharmacol. 1998;125: 969-978.
5. Seki A, Hagiwara N, Kasanuki H. Effects of propafenone on K currents in human atrial myocytes. Br J Pharmacol. 1999;126:1153-1162.
6. Snyders DJ, Knoth KM, Roberds SL, et al. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol. 1992;41:322-330.
7. Singarayar S, Bursill J, Wyse KR, et al. Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. J Cardiovasc Electrophysiol. 2003;14:641-650.
8. + channel cDNAs from human ventricle. FASEB J. 1991;5:331-337.
9. + channel current. Circ Res. 1993;73:210-216.
10. + current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73: 1061-1076.
11. Amos GJ, Wettwer E, Metzger F, et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol. 1996;491:31-50.
12. to) in normal and diseased myocardium. J Mol Cell Cardiol. 2001;33:851-872.
13. + channel in ventricular muscle: a molecular correlate for the transient outward current. Circ Res. 1996;79:659-668.
14. + current in rabbit and human atrial myocytes. Circ Res. 1999;84:551-561.
15. + channels in human atrium. Basic Res Cardiol. 2002;97:424-433.
16. Decher N, Uyguner O, Scherer CR, et al. hKChIP2 is a functional modifier of hKv4.3 potassium channels: cloning and expression of a short hKCh1P2 splice variant. Cardiovasc Res. 2001;52:255-264.
17. Goldstein RN, Khrestian C, Carlsson L, et al. AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol. 2004;15:1444-1450.
18. Carlsson L, Duker G, Linhardt G. AZD7009-A new atrial antifibrillatory compound that markedly delays atrial refractoriness and possesses low proarrhythmic activity in the anaesthetised rabbit. Eur Heart J. 2004;6: 2939.
19. Persson F, Carlsson L, Duker G, et al, Blocking characteristics of hERG, hNav1.5 and hKvLQT1/hminK after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Electrophysiol. 2005;16: 329-341.
20. Hamill OP, Marty A, Neher E, et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100.
21. + channel currents. Eur Biophys J. 2000;29:555-557.
22. + channels expressed in HEK293 cells. Br J Pharmacol. 2003;139:533-544.
23. + channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther. 1994;269:66-74.
24. Cahill SA, Kirshenbaum LA, Gross GJ. Transient outward inhibition by propafenone and 5-hydroxypropafenone in cultured neonatal rat ventricular myocytes. J Cardiovasc Pharmacol. 2001;38:460-467.
25. Wang Z, Fermini B, Nattel S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents inhuman atrial myocytes. J Pharmacol Exp Ther. 1995;272:184-196.
26. Duker G, Björkman JA, Linhardt G, et al. AZD7009-A new atrial antifibrillatory compound that markedly delays atrial refractoriness in the anaesthetised dog. Heart Rhythm. 2004;1:S159.
27. Kr (dofetilide/ibutilide) in electrically remodeled atria of the goat. Circulation. 2003;108(suppl): IV-84.